DDrare: Database of Drug Development for Rare Diseases

Searched query = "Pituitary ADH secretion disorder", "Inappropriate antidiuretic hormone secretion", "Syndrome of inappropriate secretion of antidiuretic hormone", "Inappropriate ADH syndrome", "Syndrome of inappropriate ADH", "Central diabetes insipidus", "Syndrome of inappropriate secretion of ADH", "SIADH"
The queries were searched in Public_title, Scientific_title, and Condition. Export date: 03/15/2021. Trials are sorted by Date_enrollment from most recent to oldest in the table.

Drug = C03XA01; Desmopressin; Desmopressin Oral Melt; Desmopressin intranasal; Empagliflozin; Empagliflozin 25 MG; Empagliflozin 25mg; Empagliflozin 25mg Tbl; IUPAC; Other: Fluid Restriction; Other: Induced hypotonic hyponatremia - SIAD model; SAMSCA*10CPR 15MG; SR121463B; Samsca; Satavaptan; Satavaptan (SR121463); Satavaptan (SR121463B); TOLVAPTAN; Tolvaptan; Tolvaptan Oral Tablet; Tolvaptan in euvolemic hyponatremia; Urea

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT04447911 (ClinicalTrials.gov)	January 2021	10/6/2020	Effects of the SGLT2 Inhibitor Empagliflozin in Patients With Euvolemic and Hypervolemic Hyponatremia	Effects of the SGLT2 Inhibitor Empagliflozin in Patients With Euvolemic and Hypervolemic Hyponatremia - a Monocentric Randomized Double-blind Placebo-controlled Trial (the EMPOWER Study)	Hyponatremia;SIADH;Liver Failure;Kidney Failure	Drug: Empagliflozin 25 MG;Drug: Placebo	University Hospital, Basel, Switzerland	NULL	Not yet recruiting	18 Years	N/A	All	172	Phase 4	NULL

No.

TrialID

Date_
enrollment

Date_
registration

Public_title

Scientific_title

Condition

Intervention

Primary_
sponsor

Secondary_
sponsor

Recruitment_
Status

Inclusion_
agemin

Inclusion_
agemax

Inclusion_
gender

Target_
size

Phase

Countries

NCT04447911
(ClinicalTrials.gov)

January 2021

10/6/2020

Effects of the SGLT2 Inhibitor Empagliflozin in Patients With Euvolemic and Hypervolemic Hyponatremia

Effects of the SGLT2 Inhibitor Empagliflozin in Patients With Euvolemic and Hypervolemic Hyponatremia - a Monocentric Randomized Double-blind Placebo-controlled Trial (the EMPOWER Study)

Hyponatremia;SIADH;Liver Failure;Kidney Failure

Drug: Empagliflozin 25 MG;Drug: Placebo

University Hospital, Basel, Switzerland

NULL

Not yet recruiting

18 Years

N/A

All

172

Phase 4

NULL